SINGLE INSTITUTION RESULTS OF FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER (MCRC)

被引：0
|
作者：
Barkmanova, Jaroslava [1 ]
Petruzelka, Lubos [1 ,2 ]
Sedlackova, Eva [1 ,2 ]
Vocka, Michal [1 ,2 ]
Hejduk, Karel [3 ]
Bortlicek, Zbynek [3 ]
机构：
[1] Fac Med 1, Dept Oncol, Prague 2, Czech Republic
[2] Gen Fac Hosp Prague, Prague 2, Czech Republic
[3] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu165.239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 0244
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [32] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [33] Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
    Mooi, Jennifer
    Chionh, Fiona
    Savas, Peter
    Duarte, Jessica Da Gama
    Chong, Geoffrey
    Brown, Stephen
    Wong, Rachel
    Price, Timothy J.
    Wann, Alysson
    Skrinos, Effie
    Mariadason, John M.
    Tebbutt, Niall C.
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2159 - 2167
  • [34] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    CHEMOTHERAPY, 2017, 62 (01) : 80 - 84
  • [35] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [36] Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
    Whyte, S.
    Pandor, A.
    Stevenson, M.
    Rees, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [37] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [38] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
    Kim, Youjin
    Kim, Tae Won
    Han, Sae Won
    Ahn, Joong Bae
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2019, 51 (03): : 1128 - 1134
  • [40] FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC).
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Antoniotti, Carlotta
    Marmorino, Federica
    Zoratto, Federica
    Bergamo, Francesca
    Brunetti, Isa Maura
    Pfanner, Elisabetta
    Masi, Gianluca
    Genovesi, Dario
    Filidei, Elena
    Giorgetti, Assuero
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345